H.R. 2148 · 117th Congress
Prescription Drug Price Relief Act of 2021
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 117th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
KhannaSponsor18 cosponsors · 18 D
D
Bowman
PD
D
DeFazio
RD
D
DeLauro
PJ
D
Jayapal
MJ
D
Jones
BL
D
Lee
EN
D
Norton
JN
D
Neguse
AO
D
Ocasio-Cortez
IO
D
Omar
MP
D
Pocan
AP
D
Pressley
JR
D
Raskin
JS
D
Schakowsky
RT
D
Tlaib
PW
D
Welch
CB
D
Bush
MD
D
DeSaulnier16 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.
What it does: CRS summary · Introduced in House · Mar 23, 2021
Prescription Drug Price Relief Act of 2021
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.
Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.
Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.
The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Prescription Drug Price Relief Act of 2021
Latest action (Oct 19, 2021): Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Policy area: Health · Origin: House · Introduced: Mar 23, 2021
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.